242 related articles for article (PubMed ID: 19140957)
1. The identification of peroxisome proliferator-activated receptor alpha-independent effects of oleoylethanolamide on intestinal transit in mice.
Cluny NL; Keenan CM; Lutz B; Piomelli D; Sharkey KA
Neurogastroenterol Motil; 2009 Apr; 21(4):420-9. PubMed ID: 19140957
[TBL] [Abstract][Full Text] [Related]
2. Oleoylethanolamine and palmitoylethanolamine modulate intestinal permeability in vitro via TRPV1 and PPARα.
Karwad MA; Macpherson T; Wang B; Theophilidou E; Sarmad S; Barrett DA; Larvin M; Wright KL; Lund JN; O'Sullivan SE
FASEB J; 2017 Feb; 31(2):469-481. PubMed ID: 27623929
[TBL] [Abstract][Full Text] [Related]
3. Palmitoylethanolamide normalizes intestinal motility in a model of post-inflammatory accelerated transit: involvement of CB₁ receptors and TRPV1 channels.
Capasso R; Orlando P; Pagano E; Aveta T; Buono L; Borrelli F; Di Marzo V; Izzo AA
Br J Pharmacol; 2014 Sep; 171(17):4026-37. PubMed ID: 24818658
[TBL] [Abstract][Full Text] [Related]
4. The OEA effect on food intake is independent from the presence of PPARα in the intestine and the nodose ganglion, while the impact of OEA on energy expenditure requires the presence of PPARα in mice.
Caillon A; Duszka K; Wahli W; Rohner-Jeanrenaud F; Altirriba J
Metabolism; 2018 Oct; 87():13-17. PubMed ID: 29936173
[TBL] [Abstract][Full Text] [Related]
5. Orally administered oleoylethanolamide protects mice from focal cerebral ischemic injury by activating peroxisome proliferator-activated receptor α.
Zhou Y; Yang L; Ma A; Zhang X; Li W; Yang W; Chen C; Jin X
Neuropharmacology; 2012 Aug; 63(2):242-9. PubMed ID: 22480617
[TBL] [Abstract][Full Text] [Related]
6. Cannabinoid activation of PPAR alpha; a novel neuroprotective mechanism.
Sun Y; Alexander SP; Garle MJ; Gibson CL; Hewitt K; Murphy SP; Kendall DA; Bennett AJ
Br J Pharmacol; 2007 Nov; 152(5):734-43. PubMed ID: 17906680
[TBL] [Abstract][Full Text] [Related]
7. Palmitoylethanolamide, a naturally occurring lipid, is an orally effective intestinal anti-inflammatory agent.
Borrelli F; Romano B; Petrosino S; Pagano E; Capasso R; Coppola D; Battista G; Orlando P; Di Marzo V; Izzo AA
Br J Pharmacol; 2015 Jan; 172(1):142-58. PubMed ID: 25205418
[TBL] [Abstract][Full Text] [Related]
8. Biological functions and metabolism of oleoylethanolamide.
Thabuis C; Tissot-Favre D; Bezelgues JB; Martin JC; Cruz-Hernandez C; Dionisi F; Destaillats F
Lipids; 2008 Oct; 43(10):887-94. PubMed ID: 18704536
[TBL] [Abstract][Full Text] [Related]
9. N-oleoylethanolamide suppresses intimal hyperplasia after balloon injury in rats through AMPK/PPARα pathway.
Zhao Y; Liu Y; Jing Z; Peng L; Jin P; Lin Y; Zhou Y; Yang L; Ren J; Xie Q; Jin X
Biochem Biophys Res Commun; 2018 Feb; 496(2):415-421. PubMed ID: 29305859
[TBL] [Abstract][Full Text] [Related]
10. Oleoylethanolamide dose-dependently attenuates cocaine-induced behaviours through a PPARα receptor-independent mechanism.
Bilbao A; Blanco E; Luque-Rojas MJ; Suárez J; Palomino A; Vida M; Araos P; Bermúdez-Silva FJ; Fernández-Espejo E; Spanagel R; Rodríguez de Fonseca F
Addict Biol; 2013 Jan; 18(1):78-87. PubMed ID: 23163925
[TBL] [Abstract][Full Text] [Related]
11. Naphthalen-1-yl-(4-pentyloxynaphthalen-1-yl)methanone (SAB378), a peripherally restricted cannabinoid CB1/CB2 receptor agonist, inhibits gastrointestinal motility but has no effect on experimental colitis in mice.
Cluny NL; Keenan CM; Duncan M; Fox A; Lutz B; Sharkey KA
J Pharmacol Exp Ther; 2010 Sep; 334(3):973-80. PubMed ID: 20571060
[TBL] [Abstract][Full Text] [Related]
12. Oleoylethanolamide alleviates macrophage formation via AMPK/PPARα/STAT3 pathway.
Zhao Y; Yan L; Peng L; Huang X; Zhang G; Chen B; Ren J; Zhou Y; Yang L; Peng L; Jin X; Wang Y
Pharmacol Rep; 2018 Dec; 70(6):1185-1194. PubMed ID: 30336422
[TBL] [Abstract][Full Text] [Related]
13. A role for O-1602 and G protein-coupled receptor GPR55 in the control of colonic motility in mice.
Li K; Fichna J; Schicho R; Saur D; Bashashati M; Mackie K; Li Y; Zimmer A; Göke B; Sharkey KA; Storr M
Neuropharmacology; 2013 Aug; 71(100):255-63. PubMed ID: 23603203
[TBL] [Abstract][Full Text] [Related]
14. Endocannabinoids and endocannabinoid-like compounds modulate hypoxia-induced permeability in CaCo-2 cells via CB
Karwad MA; Couch DG; Wright KL; Tufarelli C; Larvin M; Lund J; O'Sullivan SE
Biochem Pharmacol; 2019 Oct; 168():465-472. PubMed ID: 31325449
[TBL] [Abstract][Full Text] [Related]
15. Inhibitory effect of the anorexic compound oleoylethanolamide on gastric emptying in control and overweight mice.
Aviello G; Matias I; Capasso R; Petrosino S; Borrelli F; Orlando P; Romano B; Capasso F; Di Marzo V; Izzo AA
J Mol Med (Berl); 2008 Apr; 86(4):413-22. PubMed ID: 18278475
[TBL] [Abstract][Full Text] [Related]
16. Localization of cannabinoid receptors CB1, CB2, GPR55, and PPARα in the canine gastrointestinal tract.
Galiazzo G; Giancola F; Stanzani A; Fracassi F; Bernardini C; Forni M; Pietra M; Chiocchetti R
Histochem Cell Biol; 2018 Aug; 150(2):187-205. PubMed ID: 29882158
[TBL] [Abstract][Full Text] [Related]
17. Central administrations of hemopressin and related peptides inhibit gastrointestinal motility in mice.
Li XH; Lin ML; Wang ZL; Wang P; Tang HH; Lin YY; Li N; Fang Q; Wang R
Neurogastroenterol Motil; 2016 Jun; 28(6):891-9. PubMed ID: 26991932
[TBL] [Abstract][Full Text] [Related]
18. Differential effects of CB(1) neutral antagonists and inverse agonists on gastrointestinal motility in mice.
Storr MA; Bashashati M; Hirota C; Vemuri VK; Keenan CM; Duncan M; Lutz B; Mackie K; Makriyannis A; Macnaughton WK; Sharkey KA
Neurogastroenterol Motil; 2010 Jul; 22(7):787-96, e223. PubMed ID: 20180825
[TBL] [Abstract][Full Text] [Related]
19. In vivo brain levels of acetylcholine and 5-hydroxytryptamine after oleoylethanolamide or palmitoylethanolamide administrations are mediated by PPARα engagement.
Murillo-Rodríguez E; Arankowsky-Sandoval G; Budde H; Imperatori C; Machado S; Yamamoto T; Yadollahpour A; Torterolo P
Eur J Neurosci; 2021 Sep; 54(6):5932-5950. PubMed ID: 34396611
[TBL] [Abstract][Full Text] [Related]
20. Analgesic properties of oleoylethanolamide (OEA) in visceral and inflammatory pain.
Suardíaz M; Estivill-Torrús G; Goicoechea C; Bilbao A; Rodríguez de Fonseca F
Pain; 2007 Dec; 133(1-3):99-110. PubMed ID: 17449181
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
